All In Biotech

Drug Trial Radar · NCT07656415

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

159

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

Aug 2029

Study completion Aug 2030

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.

Conditions

  • Sickle Cell Disease

Interventions

  • Mitapivat Matched PlaceboDrug

    Tablets

  • MitapivatDrug

    Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects who are Transfusion Free From Week 4 Through Week 52Time frame: Week 4 through Week 52

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana Hemophilia & Thrombosis Center

    Indianapolis, Indiana · Recruiting

  • The Cancer and Hematology Centers (CHC)

    Grand Rapids, Michigan · Recruiting

  • Southern Specialty Clinic

    Flowood, Mississippi · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.